Prevalence and assessment tools of cancer-related cognitive impairment in lung cancer survivors: a systematic review and proportional meta-analysis
Распространенность и инструменты оценки когнитивных нарушений, связанных с раком, у людей, перенесших рак легкого: систематический обзор и пропорциональный метаанализ
2024-03-05
SCID: 54.1/xj4srct9
Discuss with AI
International Cognition and Cancer Task Force criteriacancer-related cognitive impairmentlung cancer survivorsproportional meta-analysissystematic review
Figures from the paper
Abstract (AI)
Abstract Purpose Cancer-related cognitive impairment (CRCI) is a significant risk factor influencing the quality of life in lung cancer survivors. No absolute assessment tool has been confirmed to assess CRCI in lung cancer survivors. This review was undertaken to pool the overall prevalence of CRCI and to summarize the assessment tools in assessing CRCI among lung cancer survivors. Methods PubMed, Cochrane Library, Embase, CINAHL, and CNKI were searched to retrieve articles reported CRCI prevalence. Summary prevalence estimates were pooled using a random effects model, along with corresponding 95% prediction intervals (PIs). The Freeman-Tukey double arcsine transformation of proportions was incorporated in the analysis. Additionally, subgroup analysis, meta-regression, and leave-one-out analysis were performed. Results A total of 12 studies, involving 1934 survivors, were included in the review. All of these studies were found to have a low risk of bias in terms of their methodological quality. Four studies (33.3%) utilized the International Cognition and Cancer Task Force (ICCTF) criteria to identify CRCI through neuropsychological tests. The pooled prevalence rate of CRCI was found to be 26% (95% PI, 16–37%), I2 = 95.97%. The region in which the studies were conducted was identified as a significant factor contributing to this heterogeneity (p = 0.013). No indication of small-study effects was found (Egger’s test: p = 0.9191). Conclusion This review provides an overview of CRCI prevalence and assessment tools in lung cancer survivors. The findings can serve as epidemiological evidence to enhance clinicians’ and researchers’ understanding of early detection and assessment.
Key Findings
1
A systematic review included 12 low-risk-of-bias studies comprising 1,934 lung cancer survivors.
2
No evidence of small-study effects was detected according to Egger’s test (p = 0.9191).
3
Only four studies (33.3%) used International Cognition and Cancer Task Force criteria with neuropsychological tests to identify cognitive impairment.
4
Substantial heterogeneity was observed across studies (I² = 95.97%), and study region significantly contributed to this variability (p = 0.013).
5
The pooled prevalence of cancer-related cognitive impairment was 26%, with a 95% prediction interval of 16–37%.
Research Object
lung cancer survivors
Research Subject
the prevalence of cancer-related cognitive impairment and the assessment tools and criteria used to identify it
Publication Details
Publication Date
2024-03-05
Journal
Publisher
ISSN
Cited by
28
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai6
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews2021
The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants2017
Meta-analysis of Observational Studies in Epidemiology A Proposal for Reporting2000
Cancer statistics, 20232023
Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management2023
A narrative review of risk factors and interventions for cancer- related cognitive impairment2021